Last 12 months
Inside the activity.
0 purchase rows · 169 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 23 |
| Dec 2025 | 0 | 18 |
| Jan 2026 | 0 | 44 |
| Feb 2026 | 0 | 22 |
| Mar 2026 | 0 | 8 |
| Apr 2026 | 0 | 10 |
| May 2026 | 0 | 19 |
| Jun 2026 | 0 | 13 |
| Jul 2026 | 0 | 7 |
| Aug 2026 | 0 | 4 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 12, 2024 Filed Sep 16, 2024 20:46 UTC |
Flammer Martina M.D.Chief Medical Officer
|
SaleCommon Stock | 635 | $74.92 | $47,574.20 |
DisclosureSEC source: 0001628280-24-040521 · wk-form4_1726519585.xml · nonDerivative · entry 2 Flammer Martina M.D. · CIK 0001796960 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 106,134 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: This is the weighted average sales price representing 635 shares sold at prices ranging from $74.90 to $74.93 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| September 12, 2024 Filed Sep 16, 2024 20:46 UTC |
Flammer Martina M.D.Chief Medical Officer
|
Exercise / conversionCommon Stock | 635 | $34.03 | $21,609.05 |
DisclosureSEC source: 0001628280-24-040521 · wk-form4_1726519585.xml · nonDerivative · entry 1 Flammer Martina M.D. · CIK 0001796960 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 106,769 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| September 10, 2024 Filed Sep 10, 2024 23:49 UTC |
Schaeffer Orlov S NicoleChief People Strategy Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 37,575 | $0.00 Strike: $10.85 | $0.00 |
DisclosureSEC source: 0001628280-24-040063 · wk-form4_1726012171.xml · derivative · entry 4 Schaeffer Orlov S Nicole · CIK 0001401017 · Chief People Strategy Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 37,575 shares Expires 2026-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable. Read SEC document |
| September 10, 2024 Filed Sep 10, 2024 23:49 UTC |
Schaeffer Orlov S NicoleChief People Strategy Officer
|
SaleCommon Stock | 9,582 | $71.88 | $688,754.16 |
DisclosureSEC source: 0001628280-24-040063 · wk-form4_1726012171.xml · nonDerivative · entry 3 Schaeffer Orlov S Nicole · CIK 0001401017 · Chief People Strategy Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 100,100 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · price: This is the weighted average sales price representing 9,582 shares sold at prices ranging from $71.80 to $72.06 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| September 10, 2024 Filed Sep 10, 2024 23:49 UTC |
Schaeffer Orlov S NicoleChief People Strategy Officer
|
SaleCommon Stock | 27,993 | $71.37 | $1,997,860.41 |
DisclosureSEC source: 0001628280-24-040063 · wk-form4_1726012171.xml · nonDerivative · entry 2 Schaeffer Orlov S Nicole · CIK 0001401017 · Chief People Strategy Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 109,682 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: This is the weighted average sales price representing 27,993 shares sold at prices ranging from $70.79 to $71.79 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| September 10, 2024 Filed Sep 10, 2024 23:49 UTC |
Schaeffer Orlov S NicoleChief People Strategy Officer
|
Exercise / conversionCommon Stock | 37,575 | $10.85 | $407,688.75 |
DisclosureSEC source: 0001628280-24-040063 · wk-form4_1726012171.xml · nonDerivative · entry 1 Schaeffer Orlov S Nicole · CIK 0001401017 · Chief People Strategy Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 137,675 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| September 06, 2024 Filed Sep 10, 2024 20:06 UTC |
Flammer Martina M.D.Chief Medical Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 19,423 | $0.00 Strike: $17.07 | $0.00 |
DisclosureSEC source: 0001628280-24-040022 · wk-form4_1725998753.xml · derivative · entry 15 Flammer Martina M.D. · CIK 0001796960 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 84,167 Underlying: Common Stock · 19,423 shares Expires 2032-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F5 · derivative.exercise_date: The options become exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| September 06, 2024 Filed Sep 10, 2024 20:06 UTC |
Flammer Martina M.D.Chief Medical Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 14,130 | $0.00 Strike: $23.75 | $0.00 |
DisclosureSEC source: 0001628280-24-040022 · wk-form4_1725998753.xml · derivative · entry 14 Flammer Martina M.D. · CIK 0001796960 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,130 shares Expires 2030-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F6 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable. Read SEC document |
| September 06, 2024 Filed Sep 10, 2024 20:06 UTC |
Flammer Martina M.D.Chief Medical Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 34,280 | $0.00 Strike: $26.43 | $0.00 |
DisclosureSEC source: 0001628280-24-040022 · wk-form4_1725998753.xml · derivative · entry 13 Flammer Martina M.D. · CIK 0001796960 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,280 Underlying: Common Stock · 34,280 shares Expires 2032-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F5 · derivative.exercise_date: The options become exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| September 06, 2024 Filed Sep 10, 2024 20:06 UTC |
Flammer Martina M.D.Chief Medical Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 18,874 | $0.00 Strike: $23.66 | $0.00 |
DisclosureSEC source: 0001628280-24-040022 · wk-form4_1725998753.xml · derivative · entry 12 Flammer Martina M.D. · CIK 0001796960 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,874 shares Expires 2030-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F6 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable. Read SEC document |
| September 06, 2024 Filed Sep 10, 2024 20:06 UTC |
Flammer Martina M.D.Chief Medical Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 25,740 | $0.00 Strike: $26.46 | $0.00 |
DisclosureSEC source: 0001628280-24-040022 · wk-form4_1725998753.xml · derivative · entry 11 Flammer Martina M.D. · CIK 0001796960 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,900 Underlying: Common Stock · 25,740 shares Expires 2031-05-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F5 · derivative.exercise_date: The options become exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| September 06, 2024 Filed Sep 10, 2024 20:06 UTC |
Flammer Martina M.D.Chief Medical Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 36,555 | $0.00 Strike: $18.95 | $0.00 |
DisclosureSEC source: 0001628280-24-040022 · wk-form4_1725998753.xml · derivative · entry 10 Flammer Martina M.D. · CIK 0001796960 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 109,665 Underlying: Common Stock · 36,555 shares Expires 2033-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F5 · derivative.exercise_date: The options become exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| September 06, 2024 Filed Sep 10, 2024 20:06 UTC |
Flammer Martina M.D.Chief Medical Officer
|
SaleCommon Stock | 9,064 | $72.61 | $658,137.04 |
DisclosureSEC source: 0001628280-24-040022 · wk-form4_1725998753.xml · nonDerivative · entry 9 Flammer Martina M.D. · CIK 0001796960 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 106,134 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · price: This is the weighted average sales price representing 9,064 shares sold at prices ranging from $72.23 to $73.07 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| September 06, 2024 Filed Sep 10, 2024 20:06 UTC |
Flammer Martina M.D.Chief Medical Officer
|
SaleCommon Stock | 63,483 | $71.43 | $4,534,590.69 |
DisclosureSEC source: 0001628280-24-040022 · wk-form4_1725998753.xml · nonDerivative · entry 8 Flammer Martina M.D. · CIK 0001796960 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 115,198 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · price: This is the weighted average sales price representing 63,483 shares sold at prices ranging from $71.21 to $72.19 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| September 06, 2024 Filed Sep 10, 2024 20:06 UTC |
Flammer Martina M.D.Chief Medical Officer
|
SaleCommon Stock | 76,455 | $70.90 | $5,420,659.50 |
DisclosureSEC source: 0001628280-24-040022 · wk-form4_1725998753.xml · nonDerivative · entry 7 Flammer Martina M.D. · CIK 0001796960 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 178,681 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: This is the weighted average sales price representing 76,455 shares sold at prices ranging from $70.20 to $71.20 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| September 06, 2024 Filed Sep 10, 2024 20:06 UTC |
Flammer Martina M.D.Chief Medical Officer
|
Exercise / conversionCommon Stock | 19,423 | $17.07 | $331,550.61 |
DisclosureSEC source: 0001628280-24-040022 · wk-form4_1725998753.xml · nonDerivative · entry 6 Flammer Martina M.D. · CIK 0001796960 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 255,136 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| September 06, 2024 Filed Sep 10, 2024 20:06 UTC |
Flammer Martina M.D.Chief Medical Officer
|
Exercise / conversionCommon Stock | 14,130 | $23.75 | $335,587.50 |
DisclosureSEC source: 0001628280-24-040022 · wk-form4_1725998753.xml · nonDerivative · entry 5 Flammer Martina M.D. · CIK 0001796960 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 235,713 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| September 06, 2024 Filed Sep 10, 2024 20:06 UTC |
Flammer Martina M.D.Chief Medical Officer
|
Exercise / conversionCommon Stock | 34,280 | $26.43 | $906,020.40 |
DisclosureSEC source: 0001628280-24-040022 · wk-form4_1725998753.xml · nonDerivative · entry 4 Flammer Martina M.D. · CIK 0001796960 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 221,583 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| September 06, 2024 Filed Sep 10, 2024 20:06 UTC |
Flammer Martina M.D.Chief Medical Officer
|
Exercise / conversionCommon Stock | 18,874 | $23.66 | $446,558.84 |
DisclosureSEC source: 0001628280-24-040022 · wk-form4_1725998753.xml · nonDerivative · entry 3 Flammer Martina M.D. · CIK 0001796960 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 187,303 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| September 06, 2024 Filed Sep 10, 2024 20:06 UTC |
Flammer Martina M.D.Chief Medical Officer
|
Exercise / conversionCommon Stock | 25,740 | $26.46 | $681,080.40 |
DisclosureSEC source: 0001628280-24-040022 · wk-form4_1725998753.xml · nonDerivative · entry 2 Flammer Martina M.D. · CIK 0001796960 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 168,429 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| September 06, 2024 Filed Sep 10, 2024 20:06 UTC |
Flammer Martina M.D.Chief Medical Officer
|
Exercise / conversionCommon Stock | 36,555 | $18.95 | $692,717.25 |
DisclosureSEC source: 0001628280-24-040022 · wk-form4_1725998753.xml · nonDerivative · entry 1 Flammer Martina M.D. · CIK 0001796960 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 142,689 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| August 29, 2024 Filed Sep 3, 2024 20:10 UTC |
SHAROKY MELVIN MDDirector
|
GiftCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-039120 · wk-form4_1725394221.xml · nonDerivative · entry 2 SHAROKY MELVIN MD · CIK 0001182633 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By The Sharoky Family Foundation, Inc. Disclosed balance after: 17,714 F1 · ownership.nature: The Reporting Person is Chairman of The Sharoky Family Foundation, Inc. and is one of three individuals who currently share voting and investment power over the shares held by The Sharoky Family Foundation, Inc. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| August 29, 2024 Filed Sep 3, 2024 20:10 UTC |
SHAROKY MELVIN MDDirector
|
GiftCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-039120 · wk-form4_1725394221.xml · nonDerivative · entry 1 SHAROKY MELVIN MD · CIK 0001182633 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 298,177 Read SEC document |
| August 12, 2024 Filed Aug 14, 2024 20:28 UTC |
Smith Michael AlexanderChief Legal Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 34,530 | $0.00 Strike: $17.07 | $0.00 |
DisclosureSEC source: 0001628280-24-037226 · wk-form4_1723667301.xml · derivative · entry 8 Smith Michael Alexander · CIK 0001870278 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,530 Underlying: Common Stock · 34,530 shares Expires 2032-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The options become exercisable based on the following vesting schedule: 25% vest on the first anniversary of the grant date and an additional 12.5% vest every six months thereafter through the fourth anniversary of the date of grant. Read SEC document |
| August 12, 2024 Filed Aug 14, 2024 20:28 UTC |
Smith Michael AlexanderChief Legal Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 41,640 | $0.00 Strike: $13.91 | $0.00 |
DisclosureSEC source: 0001628280-24-037226 · wk-form4_1723667301.xml · derivative · entry 7 Smith Michael Alexander · CIK 0001870278 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 41,640 shares Expires 2029-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable. Read SEC document |
| August 12, 2024 Filed Aug 14, 2024 20:28 UTC |
Smith Michael AlexanderChief Legal Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 11,900 | $0.00 Strike: $17.16 | $0.00 |
DisclosureSEC source: 0001628280-24-037226 · wk-form4_1723667301.xml · derivative · entry 6 Smith Michael Alexander · CIK 0001870278 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,900 shares Expires 2027-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable. Read SEC document |
| August 12, 2024 Filed Aug 14, 2024 20:28 UTC |
Smith Michael AlexanderChief Legal Officer
|
SaleCommon Stock | 20,415 | $73.65 | $1,503,564.75 |
DisclosureSEC source: 0001628280-24-037226 · wk-form4_1723667301.xml · nonDerivative · entry 5 Smith Michael Alexander · CIK 0001870278 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,727 F2 · price: This is the weighted average sales price representing 20,415 shares sold at prices ranging from $73.22 to $74.11 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| August 12, 2024 Filed Aug 14, 2024 20:28 UTC |
Smith Michael AlexanderChief Legal Officer
|
SaleCommon Stock | 67,655 | $72.75 | $4,921,901.25 |
DisclosureSEC source: 0001628280-24-037226 · wk-form4_1723667301.xml · nonDerivative · entry 4 Smith Michael Alexander · CIK 0001870278 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,142 F1 · price: This is the weighted average sales price representing 67,655 shares sold at prices ranging from $72.22 to $73.22 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| August 12, 2024 Filed Aug 14, 2024 20:28 UTC |
Smith Michael AlexanderChief Legal Officer
|
Exercise / conversionCommon Stock | 34,530 | $17.07 | $589,427.10 |
DisclosureSEC source: 0001628280-24-037226 · wk-form4_1723667301.xml · nonDerivative · entry 3 Smith Michael Alexander · CIK 0001870278 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 176,797 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 12, 2024 Filed Aug 14, 2024 20:28 UTC |
Smith Michael AlexanderChief Legal Officer
|
Exercise / conversionCommon Stock | 41,640 | $13.91 | $579,212.40 |
DisclosureSEC source: 0001628280-24-037226 · wk-form4_1723667301.xml · nonDerivative · entry 2 Smith Michael Alexander · CIK 0001870278 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 142,267 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 12, 2024 Filed Aug 14, 2024 20:28 UTC |
Smith Michael AlexanderChief Legal Officer
|
Exercise / conversionCommon Stock | 11,900 | $17.16 | $204,204.00 |
DisclosureSEC source: 0001628280-24-037226 · wk-form4_1723667301.xml · nonDerivative · entry 1 Smith Michael Alexander · CIK 0001870278 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,627 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 12, 2024 Filed Aug 14, 2024 20:26 UTC |
Schaeffer Orlov S NicoleChief People Strategy Officer
|
SaleCommon Stock | 9,469 | $72.49 | $686,407.81 |
DisclosureSEC source: 0001628280-24-037223 · wk-form4_1723667167.xml · nonDerivative · entry 1 Schaeffer Orlov S Nicole · CIK 0001401017 · Chief People Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,100 F1 · price: This is the weighted average sales price representing 9,469 shares sold at prices ranging from $72.36 to $72.63 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. F2 · balance_after: Includes 809 shares acquired through the Company's 2018 Employee Stock Purchase Plan. Read SEC document |
| July 08, 2024 Filed Jul 10, 2024 21:19 UTC |
Smith Michael AlexanderChief Legal Officer
|
Tax withholdingCommon Stock | 730 | $70.05 | $51,136.50 |
DisclosureSEC source: 0001628280-24-031618 · wk-form4_1720646371.xml · nonDerivative · entry 1 Smith Michael Alexander · CIK 0001870278 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,727 F1 · shares: Shares withheld by the Company to satisfy tax withholding requirements on vesting of Restricted Stock Units ("RSUs"). F2 · price: Represents the closing price of Common Stock on the vesting date of the RSUs. F3 · balance_after: Includes 629 shares acquired through the Company's 2018 Employee Stock Purchase Plan. Read SEC document |
| June 10, 2024 Filed Jun 12, 2024 20:21 UTC |
Flammer Martina M.D.Chief Medical Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 21,195 | $0.00 Strike: $23.75 | $0.00 |
DisclosureSEC source: 0001628280-24-027830 · wk-form4_1718223666.xml · derivative · entry 3 Flammer Martina M.D. · CIK 0001796960 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,130 Underlying: Common Stock · 21,195 shares Expires 2030-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable. Read SEC document |
| June 10, 2024 Filed Jun 12, 2024 20:21 UTC |
Flammer Martina M.D.Chief Medical Officer
|
SaleCommon Stock | 21,195 | $60.00 | $1,271,700.00 |
DisclosureSEC source: 0001628280-24-027830 · wk-form4_1718223666.xml · nonDerivative · entry 2 Flammer Martina M.D. · CIK 0001796960 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 106,134 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| June 10, 2024 Filed Jun 12, 2024 20:21 UTC |
Flammer Martina M.D.Chief Medical Officer
|
Exercise / conversionCommon Stock | 21,195 | $23.75 | $503,381.25 |
DisclosureSEC source: 0001628280-24-027830 · wk-form4_1718223666.xml · nonDerivative · entry 1 Flammer Martina M.D. · CIK 0001796960 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 127,329 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 20:23 UTC |
Schaeffer Orlov S NicoleChief People Strategy Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 41,250 | $0.00 Strike: $22.76 | $0.00 |
DisclosureSEC source: 0001628280-24-026851 · wk-form4_1717618996.xml · derivative · entry 5 Schaeffer Orlov S Nicole · CIK 0001401017 · Chief People Strategy Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 41,250 shares Expires 2025-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 20:23 UTC |
Schaeffer Orlov S NicoleChief People Strategy Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 13,750 | $0.00 Strike: $16.07 | $0.00 |
DisclosureSEC source: 0001628280-24-026851 · wk-form4_1717618996.xml · derivative · entry 4 Schaeffer Orlov S Nicole · CIK 0001401017 · Chief People Strategy Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,750 shares Expires 2025-01-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 20:23 UTC |
Schaeffer Orlov S NicoleChief People Strategy Officer
|
SaleCommon Stock | 55,000 | $55.33 | $3,043,150.00 |
DisclosureSEC source: 0001628280-24-026851 · wk-form4_1717618996.xml · nonDerivative · entry 3 Schaeffer Orlov S Nicole · CIK 0001401017 · Chief People Strategy Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 108,760 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: This is the weighted average sales price representing 55,000 shares sold at prices ranging from $54.69 to $55.65 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 20:23 UTC |
Schaeffer Orlov S NicoleChief People Strategy Officer
|
Exercise / conversionCommon Stock | 41,250 | $22.76 | $938,850.00 |
DisclosureSEC source: 0001628280-24-026851 · wk-form4_1717618996.xml · nonDerivative · entry 2 Schaeffer Orlov S Nicole · CIK 0001401017 · Chief People Strategy Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 163,760 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 20:23 UTC |
Schaeffer Orlov S NicoleChief People Strategy Officer
|
Exercise / conversionCommon Stock | 13,750 | $16.07 | $220,962.50 |
DisclosureSEC source: 0001628280-24-026851 · wk-form4_1717618996.xml · nonDerivative · entry 1 Schaeffer Orlov S Nicole · CIK 0001401017 · Chief People Strategy Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 122,510 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| May 30, 2024 Filed May 30, 2024 21:43 UTC |
Flammer Martina M.D.Chief Medical Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 21,195 | $0.00 Strike: $23.75 | $0.00 |
DisclosureSEC source: 0001628280-24-025890 · wk-form4_1717105381.xml · derivative · entry 6 Flammer Martina M.D. · CIK 0001796960 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,325 Underlying: Common Stock · 21,195 shares Expires 2030-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable. Read SEC document |
| May 30, 2024 Filed May 30, 2024 21:43 UTC |
Flammer Martina M.D.Chief Medical Officer
|
SaleCommon Stock | 21,195 | $55.00 | $1,165,725.00 |
DisclosureSEC source: 0001628280-24-025890 · wk-form4_1717105381.xml · nonDerivative · entry 4 Flammer Martina M.D. · CIK 0001796960 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 106,134 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| May 30, 2024 Filed May 30, 2024 21:43 UTC |
Flammer Martina M.D.Chief Medical Officer
|
Exercise / conversionCommon Stock | 21,195 | $23.75 | $503,381.25 |
DisclosureSEC source: 0001628280-24-025890 · wk-form4_1717105381.xml · nonDerivative · entry 3 Flammer Martina M.D. · CIK 0001796960 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 127,329 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| May 29, 2024 Filed May 30, 2024 21:41 UTC |
Bonstein SaraChief Financial Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 32,156 | $0.00 Strike: $17.07 | $0.00 |
DisclosureSEC source: 0001628280-24-025886 · wk-form4_1717105276.xml · derivative · entry 26 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 59,350 Underlying: Common Stock · 32,156 shares Expires 2032-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F5 · derivative.exercise_date: The options are exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant, subject to Ms. Bonstein's continued employment with the Company on each vesting date. Read SEC document |
| May 29, 2024 Filed May 30, 2024 21:41 UTC |
Bonstein SaraChief Financial Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 20,111 | $0.00 Strike: $26.43 | $0.00 |
DisclosureSEC source: 0001628280-24-025886 · wk-form4_1717105276.xml · derivative · entry 24 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,275 Underlying: Common Stock · 20,111 shares Expires 2032-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F5 · derivative.exercise_date: The options are exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant, subject to Ms. Bonstein's continued employment with the Company on each vesting date. Read SEC document |
| May 29, 2024 Filed May 30, 2024 21:41 UTC |
Bonstein SaraChief Financial Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 39,446 | $0.00 Strike: $26.46 | $0.00 |
DisclosureSEC source: 0001628280-24-025886 · wk-form4_1717105276.xml · derivative · entry 22 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,740 Underlying: Common Stock · 39,446 shares Expires 2031-05-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F5 · derivative.exercise_date: The options are exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant, subject to Ms. Bonstein's continued employment with the Company on each vesting date. Read SEC document |
| May 29, 2024 Filed May 30, 2024 21:41 UTC |
Bonstein SaraChief Financial Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 25,046 | $0.00 Strike: $34.03 | $0.00 |
DisclosureSEC source: 0001628280-24-025886 · wk-form4_1717105276.xml · derivative · entry 20 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,100 Underlying: Common Stock · 25,046 shares Expires 2031-01-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F5 · derivative.exercise_date: The options are exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant, subject to Ms. Bonstein's continued employment with the Company on each vesting date. Read SEC document |
| May 29, 2024 Filed May 30, 2024 21:41 UTC |
Bonstein SaraChief Financial Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 27,074 | $0.00 Strike: $24.70 | $0.00 |
DisclosureSEC source: 0001628280-24-025886 · wk-form4_1717105276.xml · derivative · entry 18 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,362 Underlying: Common Stock · 27,074 shares Expires 2030-05-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable. Read SEC document |
| May 29, 2024 Filed May 30, 2024 21:41 UTC |
Bonstein SaraChief Financial Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 76,731 | $0.00 Strike: $28.88 | $0.00 |
DisclosureSEC source: 0001628280-24-025886 · wk-form4_1717105276.xml · derivative · entry 16 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,455 Underlying: Common Stock · 76,731 shares Expires 2030-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.